Automatiqc® Medical Writing Technology

Innovative AI, cloud-based application to aid in quick and efficient document authoring

We appreciate the innovative spirit of MMS in enabling us to meet important milestones. Excellent job!
SVP, Research & Development
Biotechnology Sponsor

Free up resource time, improve quality, and bring efficiencies to the medical and regulatory writing process

Automatiqc® is a cloud-based solution that utilizes robotic process automation (RPA), a form of artificial intelligence (AI), to apply the required document formatting and style conventions. This frees up writers to focus on the key messaging, stakeholder alignment, and other key elements  that are most critical to the medical and regulatory writing process.

Additional key benefits of Automatiqc include:

  • Removes the burden of style and formatting from the regulatory or medical writer, saving time for critical data elements
  • Built-in set of rules that can be customized to meet any internal company or external audience document style requirements
  • Compounding efficiencies with document amendments, improving the quality of documents and reduces effort for the review and QC steps in subsequent drafts or document amendments
  • Complementary: processed documents are compatible with other tools, including PleaseReview, Veeva RIM and many others
  • Easy output provided in tracked changes for greater visibility to the writer

With this innovative medical writing technology, Automatiqc users are now able to focus where they can bring the greatest value – to the science of Medical & Regulatory Writing.

Get in touch to request a demo of Automatiqc!

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization